



Patent Application
Attorney Docket No. PC11862

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231 on this 22nd day of April 2002.

By

Evelyn Sabatino
(Signature of person mailing)
Evelyn Sabatino

(Typed or printed name of person)

RECEIVED

MAY 02 2002

TECH CENTER 1600/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bruce A. Hay, et al. :

Examiner: David Lukton

APPLICATION NO.: 09/747,437 :

Group Art Unit: 1653

FILING DATE: December 21, 2000 :

COPY OF PAPERS
ORIGINALLY FILED

TITLE: Somatostatin Antagonists and Agonists :
that Act at the SST Subtype 2 Receptor

Commissioner for Patents
Washington, D.C. 20231

Sir:

Response to Restriction Requirement

The present paper is in response to the Examiner's requirement of restriction/election mailed March 19, 2002. The following elections are made without traverse.

Applicants elect to prosecute the invention termed Group II, that is, Claims 1-4, 11-17, 21 and 25, wherein group W is option (b), termed G2 by the Examiner.

As species, Applicants elect the compound prepared according to Example 2 (page 34) of the Specification (which is also species 5 in Claim 9).

6-Amino-2-(3-(1H-indol-3-yl)-2-[[4-(toluene-4-sulfonyl)-piperazine-1-carbonyl]-amino}-propionylamino)-hexanoic acid tert-butyl ester.

Respectfully submitted,

Date:

4/22/02

E. Victor Donahue
E. Victor Donahue
Attorney for Applicant(s)
Reg. No. 35,492

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 573-2739